Authors

Latest:

Extending the Promise of Immunotherapy to Pancreatic Cancer

Stephanie K. Dougan, PhD, assistant professor, microbiology and immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways to extend the promise of immunotherapy to the field of pancreatic cancer.

Stephanie Key CMD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Stephanie L. Graff, MD, FACP

Latest:

Dr Graff on Fertility Preservation Strategies in Breast Cancer

Stephanie L. Graff, MD, FACP, FASCO, discusses current strategies for fertility preservation in patients with breast cancer.

Stephanie Silverman

Latest:

Acquisitions by 340B Hospitals Drive Up Healthcare Costs

As the 340B drug discount program has ballooned in size over the last several years, some hospitals are getting creative about how to make the program work for their own financial gain.

Stephen A. Boorjian, MD

Latest:

Dr. Boorjian on Research With Nadofaragene Firadenovec in Nonmuscle Invasive Bladder Cancer

Stephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).

Stephen Ansell, MD, PhD

Latest:

Dr. Ansell on the Updated Analysis of ECHELON-1 in Classical Hodgkin Lymphoma

Stephen M. Ansell, MD, PhD, discusses the updated analysis of the phase 3 ECHELON-1 in classical Hodgkin lymphoma.

Stephen C. Malamud, MD

Latest:

Dr. Malamud on Key Data From KATHERINE Study in HER2+ Breast Cancer

Stephen C. Malamud, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses key data from the KATHERINE study in the treatment of patients with HER2-positive breast cancer.

Stephen D. Nimer, MD

Latest:

Dr. Nimer on CAR T-Cell Therapy in Hematologic Malignancies

Stephen D. Nimer, MD, professor of medicine, director, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Stephen G Emerson, MD, PhD

Latest:

Dr. Emerson Explains the Connection Between Stem Cell Mutations and Leukemia

Stephen G Emerson, MD, PhD, Clyde Wu Professor of Immunology and Medicine, director, Herbert Irving Comprehensive Cancer Center, explains the connection between stem cell mutations and leukemia.

Stephen Grupp, MD, PhD

Latest:

Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALL

Stephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).

Stephen Huang, MD

Latest:

Dr. Stephen Huang on Challenges in Pediatric Thyroid Cancer

Stephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.

Stephen J. Freedland, MD

Latest:

Final Thoughts on CSPC

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.

Stephen J. Schuster, MD, Abramson Cancer Center

Latest:

The Expanding Role of CAR T Cells in Lymphoma and Leukemia

Stephen J. Schuster, MD, The University of Pennsylvania

Stephen J. Schuster, MD, University of Pennsylvania

Stephen Johnston, MA, PhD, FRCP, The Royal Marsden Hospital

Latest:

Dr. Johnston on the Results of monarchE With Abemaciclib in High-Risk Early Breast Cancer

Stephen Johnston, MA, PhD, FRCP, discusses the results of the phase 3 monarchE study examining the addition of abemaciclib to endocrine therapy in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.

Stephen L. Graziano, MD

Latest:

Dr. Graziano on Sequencing Targeted Therapy in NSCLC

Stephen L. Graziano, MD, professor of medicine, division chief of medicine, and division chief of Upstate Cancer Center Adult Hematology/Oncology at the Upstate University Hospital, discusses sequencing targeted therapy for patients with non–small cell lung cancer (NSCLC).

Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center

Latest:

Emerging Treatments in SCLC: Impact of Targeted Therapy

Key opinion leaders in lung cancer share personal thoughts on the potential for bispecific agents and the overall impact of inhibiting molecular targets.

Stephen Liu, MD, MedStar Georgetown University Hospital

Latest:

NSCLC Management: Second-Line Options

Stephen Liu, MD, Georgetown University Medical Center